Using this specific phenotype, one study investigated the effect of vaccination against p16 (p16-derived peptide P16_37-63) in patients with advanced HPV-associated cancers and could show a tumour response in 14 out of 20 patients and stable disease in nine patients; the vaccine was described to induce cellular and humoral immune responses (NCT01462838, Table 2) [121]. The gene discussed is CDKN2A; the disease is neoplasm.